Daily Cosmetic Research Analysis
Three randomized clinical studies in cosmetically relevant care reported meaningful benefits: a six-month double-blind RCT found an amine + zinc + fluoride toothpaste substantially reduced plaque and gingivitis versus standard fluoride paste; a double-blind RCT showed 5% atorvastatin added to ketoconazole shampoo improved scalp seborrheic dermatitis severity beyond ketoconazole alone; and a split-face, double-blind randomized study demonstrated a multi-component reaction peptide cream accelerate
Summary
Three randomized clinical studies in cosmetically relevant care reported meaningful benefits: a six-month double-blind RCT found an amine + zinc + fluoride toothpaste substantially reduced plaque and gingivitis versus standard fluoride paste; a double-blind RCT showed 5% atorvastatin added to ketoconazole shampoo improved scalp seborrheic dermatitis severity beyond ketoconazole alone; and a split-face, double-blind randomized study demonstrated a multi-component reaction peptide cream accelerated post–non-ablative fractional laser recovery and enhanced anti-aging outcomes versus standard ointment.
Research Themes
- Randomized trials of consumer-facing cosmeceuticals and adjunct therapies
- Non-steroidal topical strategies enhancing inflammatory skin disease control
- Post-procedure skincare optimizing laser rejuvenation outcomes
Selected Articles
1. Effectiveness of a novel amine + zinc + fluoride toothpaste in reducing plaque and gingivitis: results of a six-month randomized controlled trial.
In a registered, double-blind 6-month RCT (N=92), an amine + zinc + fluoride toothpaste produced greater reductions in plaque (31.2%), gingival index (32.3%), and gingival severity (49.3%) than a standard fluoride control, with more healthy sites at both site- and subject-level analyses.
Impact: Provides Level I evidence that a novel antibacterial formulation yields clinically meaningful improvements over standard fluoride toothpaste, supporting adoption in gingivitis management.
Clinical Implications: Daily use can be recommended for patients with gingivitis to reduce plaque burden and bleeding, potentially decreasing need for adjunctive antiseptics; suitable for general practice and public health programs.
Key Findings
- Double-blind RCT (N=92; site-level N=10,778) over 6 months showed superior plaque and gingival improvements with amine + zinc + fluoride toothpaste vs control.
- Mean reductions at 6 months: plaque 31.2%, gingival index 32.3%, gingival severity 49.3% in the test group.
- Trial pre-registered (NCT06563518), supporting methodological transparency.
Methodological Strengths
- Randomized, double-blind, parallel-group design with 6-month follow-up
- Pre-registered trial with both site-level and subject-level analyses
Limitations
- Single geographic region (Bangkok, Thailand) limits generalizability
- Comparator was a standard fluoride toothpaste; no active antiseptic comparator (e.g., chlorhexidine)
Future Directions: Head-to-head trials against antiseptic toothpastes and pragmatic studies in diverse populations to assess real-world effectiveness and safety over longer durations.
OBJECTIVES: To evaluate the efficacy of a toothpaste containing amine compound, 0.5% zinc lactate, and 1400 ppm F (NaF) in comparison to a regular fluoride toothpaste containing 1450 ppm F as MFP/NaF (negative control). Plaque and gingivitis indices were determined over a 6-month period. MATERIALS AND METHODS: In a randomized, double-blind, two-cell, parallel-group design on healthy adults from the Bangkok, Thailand area presenting with initial gingivitis (Löe-Silness gingival index ≥ 1) and visible plaque (Turesky Modification-Quigley-Hein index ≥ 1.5) were assigned test and negative control toothpastes and instructed to brush twice daily for two minutes. RESULTS: Site-level (N = 10,778) and subject-level (N = 92) data indicated that the test toothpaste increased the number of healthy sites and improved gum health as compared to the negative control toothpaste. For the test group, after 6 months, the average reduction for plaque, gingival index, and gingival severity was 31.2%, 32.3%, and 49.3%, respectively. Average reductions were greater in the test group than the negative control group across all measures. CONCLUSIONS: The amine + zinc + fluoride toothpaste significantly improved measures of plaque (12× more effective) and gingivitis (5× more effective) in comparison to a standard fluoride toothpaste, suggesting that the novel formulation with antibacterial active ingredients amine and zinc facilitates more effective plaque removal, and promotes gingival health. CLINICAL RELEVANCE: These results suggest that daily use of amine + zinc + fluoride toothpaste can provide a significant improvement in managing plaque accumulation and bleeding associated with gingival inflammation especially for patients experiencing gingivitis. CLINICAL TRIAL REGISTRATION: NCT06563518 (registration date: August 19, 2024).
2. The additional effect of 5% atorvastatin shampoo in the treatment of adult patients with mild to moderate seborrheic dermatitis of the scalp: A prospective, randomised, double-blind trial.
In a double-blind RCT of 46 adults with scalp seborrheic dermatitis, adding 5% atorvastatin to 2% ketoconazole shampoo produced a greater reduction in SSSD severity (by 1.92 points; P=0.02) over 4 weeks than ketoconazole alone, with notable improvements in scaling and itch.
Impact: Demonstrates repurposing of a statin as an anti-inflammatory adjunct in SD with randomized evidence, potentially reducing symptom burden in a prevalent condition.
Clinical Implications: Consider atorvastatin-containing shampoo as an adjunct to ketoconazole for adults with mild-to-moderate scalp SD to improve scaling and pruritus over short courses; monitor tolerability.
Key Findings
- Prospective, randomized, double-blind trial with 46 adults compared ketoconazole vs ketoconazole + 5% atorvastatin for 4 weeks.
- Adjunct atorvastatin led to a greater mean reduction in SSSD by 1.92 points versus control (P=0.02).
- Symptom domains of scaling and itching improved notably with the atorvastatin-containing shampoo.
Methodological Strengths
- Randomized, double-blind design with a defined clinical severity scale (SSSD)
- Direct head-to-head adjunctive comparison against standard ketoconazole shampoo
Limitations
- Single-center study with a small sample size and short 4-week follow-up
- No long-term safety or relapse data; external validity requires confirmation
Future Directions: Larger multicenter RCTs with longer follow-up to assess durability, safety, and mechanism (e.g., anti-inflammatory pathways) of topical statin adjuncts in SD.
Background Seborrheic dermatitis (SD) is a long-lasting inflammatory skin condition that predominantly impacts regions abundant in sebaceous glands, including the scalp. Objectives To assess the efficacy and anti-inflammatory effect of atorvastatin as an additive treatment among SD patients. Methods In a prospective, randomised, double-blind trial, 46 patients over 18 years old with mild to moderate scalp SD were randomly assigned to receive either 2% ketoconazole shampoo or 2% ketoconazole shampoo plus 5% atorvastatin. The severity of dermatitis was assessed based on the symptom scale of seborrheic dermatitis (SSSD), and the variables of erythema, scaling, and itching, at baseline and 4 weeks after the intervention. Results Based on our analyses, both treatment methods significantly reduced the SSSD scores. However, the average SSSD score in patients using ketoconazole shampoo plus atorvastatin decreased by an average of five points after 1 month. This reduction was comparable to the average decline of 3.5 points observed in the group using ketoconazole shampoo alone. Specifically, the severity of dermatitis, as assessed by the SSSD score, significantly decreased by 1.92 points more, in individuals using the atorvastatin-containing shampoo compared to the comparison group (P = 0.02). Limitation This research was conducted at a single centre which limits the validity of the findings. Conclusion The results of this study suggest that shampoo containing atorvastatin provides a statistically significant effect compared to ketoconazole shampoo alone, indicating its potential as an alternative treatment for SD. The treatment notably alleviates symptoms associated with scaling and itching which are the common manifestations of the condition.
3. A Multi-Component Reaction Peptide Augmenting the Anti-Aging Benefits of Non-Ablative Laser Procedure.
In a split-face, double-blind randomized clinical study following non-ablative fractional laser resurfacing, an MCP peptide formula matched Aquaphor for healing but achieved faster and greater improvements across multiple anti-aging parameters over 28 days, supported by clinical grading, barrier assessments, OCT, and imaging.
Impact: Offers randomized human evidence that a targeted cosmeceutical can meaningfully augment post-laser rejuvenation outcomes without compromising healing kinetics.
Clinical Implications: Consider MCP peptide-containing formulations in post–non-ablative fractional laser care to accelerate cosmetic improvements while maintaining healing, potentially reducing downtime.
Key Findings
- Split-face, double-blind randomized clinical study comparing MCP peptide formula vs Aquaphor over 28 days post-laser.
- MCP matched Aquaphor for healing but showed faster kinetics and greater improvements in multiple anti-aging parameters.
- Outcomes were supported by clinical grading, skin barrier measurements, OCT, and standardized imaging.
Methodological Strengths
- Split-face design controls for inter-individual variability with double-blinding and randomization
- Multimodal outcome assessment (clinical grading, barrier metrics, OCT, imaging)
Limitations
- Single-center study with unspecified sample size limits generalizability and statistical power
- Short follow-up (28 days); no long-term durability or safety outcomes reported
Future Directions: Larger multicenter trials with quantified wrinkle/texture endpoints and patient-reported outcomes to confirm efficacy, durability, and safety; mechanistic studies on peptide-driven remodeling.
BACKGROUND: Laser resurfacing is one of the most popular aesthetic procedures that address a wide range of skin conditions and overall skin rejuvenation. To reduce downtime and improve the clinical efficacy of the procedures, it is important to design post-procedure care routines to complement them. Towards fulfilling that consumer need, a peptide synthesized from multi-component reaction (MCP) has been developed. AIMS: The objective of this study is to investigate the functionalities of MCP as a regenerative active that enhances the healing kinetics and anti-aging performance following non-ablative fractional laser resurfacing procedures. METHODS: To fulfill the objective, a single-center, split-face design, double-blinded, randomized clinical study was conducted. Study participants received a full face non-ablative fractional laser procedure followed by treatment with two topical products, MCP formula or Aquaphor Healing Ointment®or AHO (Beiersdorf Inc, Wilton, CT) as a standard of care topical agent. Both products were applied immediately after the laser procedure and continued two times daily for 28 days. Clinical evaluation and expert grading of healing and aging, instrument measurement of skin barrier function, optical coherence tomography and standardized digital imaging were performed. RESULTS: Clinical evaluation results showed that the MCP formula promoted post-procedure skin healing at a comparable level as Aquaphor Healing Ointment®. However, the MCP formula demonstrated faster kinetics and enhanced level of improvement in multiple anti-aging parameters when compared with the benchmark control. Results from this clinical study demonstrate that the use of MCP formula post non-ablative fractional laser treatment is efficacious in promoting skin healing and enhancing the anti-aging benefits provided by the procedure. J Drugs Dermatol. 2025;24(2):188-195. doi:10.36849/JDD.8066R1.